skip to Main Content

Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience

Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience
Pancreatic cancer is the third leading cause of cancer-related death in the United States, with a five-year overall survival of approximately 8% [1-2]. While surgery is the only potentially curative option, many patients are not eligible either because the disease is locally advanced or the patient is medically inoperable. In these cases, the prognosis of clinically localized or locally advanced pancreas cancer (LAPC) remains poor.

Treatment for unresectable LAPC remains controversial and includes both systemic therapy and radiotherapy [3]. The LAP07 trial reported an improvement in local control for the chemoradiotherapy (CRT) arm as compared to the chemotherapy alone arm; however, there was no difference in overall survival [4]. Read more . . . 


Back To Top